IAMA 001
Alternative Names: IAMA-001; IAMA-001 nasal sprayLatest Information Update: 24 Sep 2024
At a glance
- Originator Nanjing JSIAMA Biopharmaceuticals
- Class Antiallergics; Nucleic acids
- Mechanism of Action Protein expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Seasonal allergic rhinitis
Most Recent Events
- 09 May 2024 Phase-I clinical trials in Seasonal allergic rhinitis (In volunteers) in China (Intranasal) (CTR20241136)